<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027451</url>
  </required_header>
  <id_info>
    <org_study_id>M200C-2102</org_study_id>
    <secondary_id>U01DA045366</secondary_id>
    <nct_id>NCT05027451</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of IXT-m200</brief_title>
  <official_title>A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single-Dose Intravenous Study to Evaluate the Safety and Pharmacokinetics of IXT-m200 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InterveXion Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>InterveXion Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 9 participants will be enrolled in the study in a single cohort. Participants&#xD;
      will be randomized to 3 g IXT-m200 or placebo at 7:2. Each will receive their dose as a&#xD;
      30-min intravenous infusion, then remain at the study site overnight to complete Day 1 and&#xD;
      Day 2 assessments (e.g., electrocardiogram (ECG), laboratory assessments, blood draws, and&#xD;
      vital signs). Following discharge on Day 2, participants will return to the clinic for&#xD;
      follow-up pharmacokinetic (PK) and safety assessments on Day 8, then every 1-3 weeks&#xD;
      thereafter until Day 127.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">March 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events (AEs) assessed by physical examinations</measure>
    <time_frame>127 days</time_frame>
    <description>Physical examinations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related AEs assessed by vital signs</measure>
    <time_frame>127 days</time_frame>
    <description>Blood pressure, heart rate, and temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related AEs assessed by ECG</measure>
    <time_frame>127 days</time_frame>
    <description>Electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related AEs assessed by clinical laboratory testing</measure>
    <time_frame>127 days</time_frame>
    <description>Clinical laboratory testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of IXT-m200 concentrations</measure>
    <time_frame>127 days</time_frame>
    <description>IXT-m200 concentrations over time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IXT-m200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 g of IXT-m200 given once by 30-min intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IXT-m200</intervention_name>
    <description>Anti-methamphetamine chimeric monoclonal antibody (mAb)</description>
    <arm_group_label>IXT-m200</arm_group_label>
    <other_name>ch-mAb7F9</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Eligible participants will:&#xD;
&#xD;
          1. Be 18-65 years of age, inclusive, at the time of study consent;&#xD;
&#xD;
          2. Be able and willing to read, comprehend, and give Authorization for Use/Disclosure of&#xD;
             Health Information (HIPAA) and informed consent;&#xD;
&#xD;
          3. Be healthy, based on the pre-study medical evaluation (medical history and physical&#xD;
             exam, vital signs, ECG, and clinical laboratory evaluations);&#xD;
&#xD;
          4. Be willing to comply with study instructions and dosing, agree to make all&#xD;
             appointments, and complete the entire course of the study;&#xD;
&#xD;
          5. Be of nonchildbearing potential or agree to use protocol-specified method(s) of birth&#xD;
             control throughout study participation;&#xD;
&#xD;
          6. Agree to adhere to Lifestyle Considerations throughout study duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Eligible participants will NOT:&#xD;
&#xD;
          1. Have a history of treatment with a monoclonal antibody in the past year;&#xD;
&#xD;
          2. Have a known contraindication or sensitivity to IXT-m200 based on known allergies to&#xD;
             other mAbs, any inactive ingredient of IXT-m200, or any other products required for&#xD;
             the study procedures;&#xD;
&#xD;
          3. Have a history of alcohol and/or drug use disorder, as determined by DSM-5 criteria;&#xD;
&#xD;
          4. Have a history of stimulant use, including methamphetamine and amphetamine;&#xD;
&#xD;
          5. Be currently taking certain other drugs and medications, including: &quot;designer drugs&quot;&#xD;
             (e.g., 3,4-methylenedioxyMETH (MDMA, Ecstasy, Adam, XTC) and its N-dimethyl metabolite&#xD;
             methylenedioxyamphetamine (MDA), anti-orexigenic drugs (including over-the-counter&#xD;
             medications for weight loss), or be chronic users of phenethylamine compounds (e.g.,&#xD;
             phenylpropanolamine, ephedrine, pseudoephedrine, amphetamine, phentermine,&#xD;
             phenmetrazine, methylphenidate, diethylpropion, and propylhexedrine);&#xD;
&#xD;
          6. Have a positive drug screen for any psychoactive substances (legal or nonlegal) on Day&#xD;
             1 prior to dosing;&#xD;
&#xD;
          7. Have a history of severe allergy (rash, hives, breathing difficulty, etc) to any&#xD;
             medications;&#xD;
&#xD;
          8. Have a history of allergic or environmental bronchial asthma within the past 3 years;&#xD;
&#xD;
          9. Have a clinically significant history of or current abnormality or disease of any&#xD;
             organ system, including renal, hepatic, gastrointestinal, cardiovascular, pulmonary&#xD;
             (including chronic asthma), endocrine (eg, diabetes), central nervous (eg psychiatric&#xD;
             conditions), or hematologic systems, or recent clinically significant surgery;&#xD;
&#xD;
         10. Have a history of seizure, epilepsy, severe head injury, multiple sclerosis, or other&#xD;
             known neurological conditions;&#xD;
&#xD;
         11. Have a planned or scheduled surgical procedure during the study;&#xD;
&#xD;
         12. Have recently donated blood or plasma (within 30 days of study drug dose);&#xD;
&#xD;
         13. Have a current diagnosis of anorexia nervosa or bulimia disorder;&#xD;
&#xD;
         14. Be currently participating or has participated within the last 30 days prior to the&#xD;
             start of this study in a drug, device, or other interventional research study;&#xD;
&#xD;
         15. Be pregnant or lactating;&#xD;
&#xD;
         16. In the Investigator's or Sponsor's (or designee) opinion, be inappropriate for the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>InterveXion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinilabs Drug Development Corporation</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Final datasets are expected to contain pharmacokinetic data on IXT-m200 and safety data. No individually identifiable private information will be distributed.</ipd_description>
    <ipd_time_frame>These datasets will be available for distribution following submission to the FDA of the Clinical Study Report and publication. They will be available for 2 years after the initial publication.</ipd_time_frame>
    <ipd_access_criteria>These datasets and associated documentation will be made available on CD by the Sponsor to requestors under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology and not distributing to third parties; and (3) a commitment to destroying or returning the data after analyses are completed. Requests should be sent to intervexion@gmail.com.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

